Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy

ENVAD-HF, a prospective randomized controlled trial of angiotensin-neprilysin inhibition in stable HeartMate 3 LVAD recipients, demonstrated the safety and tolerability of this therapy in this unique population. The trial forms the basis for a pivotal trial to investigate the usefulness of HF-specific therapies in the LVAD population. (Sacubitril/Valsartan in Left Ventricular Assist Device Recipients [ENVAD-HF], NCT04103554; A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients, 2019-003888-22).

Authors

Institutions

Publication Details

Journal
JACC Heart Failure
Published
2025-08-31
DOI
https://doi.org/10.1016/j.jchf.2025.102657
Citations
4
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
2.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy

Filip Lončarić, Sylwia Wiśniowska‐Śmiałek, Nir Y. Uriel, Frank Thomas Ruschitzka et al.
4 citations
JACC Heart Failure
Mechanical Circulatory Support Devices
2.70
article

Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy

Filip Lončarić, Sylwia Wiśniowska‐Śmiałek, Nir Y. Uriel, Frank Thomas Ruschitzka, Gloria Šestan, Ulrich P. Jorde, Jasper J. Brugts, Ivo Planinc, Markéta Hegarová, Hrvoje Gašparović, Linda W. van Laake, Brian Claggett, Scott David Solomon, Mandeep R. Mehra, Davor Milicić, Filip Puškarić, Maja Čikeš, Ian J. Kulac, Nina Jakuš, Igor Rudež, Paweł Rubiś, Karol Wierzbicki, Dubravka Šipuš
article en
4 citations

Abstract

ENVAD-HF, a prospective randomized controlled trial of angiotensin-neprilysin inhibition in stable HeartMate 3 LVAD recipients, demonstrated the safety and tolerability of this therapy in this unique population. The trial forms the basis for a pivotal trial to investigate the usefulness of HF-specific therapies in the LVAD population. (Sacubitril/Valsartan in Left Ventricular Assist Device Recipients [ENVAD-HF], NCT04103554; A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients, 2019-003888-22).

JACC Heart FailureVol. 13(11)
Jagiellonian University (PL), Brigham and Women's Hospital (US), Harvard University (US), University Hospital Centre Zagreb (HR), University of Zagreb (HR), Columbia University Irving Medical Center (US), University Hospital Dubrava (HR), Erasmus MC (NL), University Medical Center Utrecht (NL), University Hospital of Zurich (CH), John Paul II Hospital (PL), Montefiore Health System (US), Institute of Clinical and Experimental Medicine (CZ), Erasmus University Rotterdam (NL)
Novartis, St. Jude Medical
Good health and well-being
Openalex Percentile: Top 10%
Mechanical Circulatory Support Devices
2.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.